AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Medicare 130

Medicare Nuclear Medicine Radiopharmaceuticals Imaging 130

Open Medscience

AUGUST 11, 2024

Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Patient Care Disease 52

AuntMinnie

JANUARY 19, 2024

Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions. Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PET scans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime.

Disease 130

Disease Medicare Imaging PET Scan 130

Open Medscience

JULY 12, 2024

PET scans are crucial for detecting metabolic activity, providing valuable insights into cancer, neurological disorders, and cardiovascular diseases. The post How to Read a PET Scan: A Basic Understanding appeared first on Open MedScience.

PET Scan 40

PET Scan Disease Imaging Modalities Medical Imaging 40

Imaging Technology

APRIL 28, 2023

This collaboration will drive continuous innovation in molecular imaging agent production to improve access to radiopharmaceuticals in South Africa and help drive precision care in the region.” GE HealthCare has signed an agreement with Axim Life Isotopes South Africa (Pty) Ltd.

Healthcare 98

Healthcare Healthcare Radiopharmaceuticals PET Scan 98

Imaging Technology

JANUARY 30, 2025

Centers for Medicare and Medicaid Services (CMS) has announced key changes to reimbursement that make advanced imaging more accessible, lifting its one-scan-per-patient restriction in 2023 and unbundling payment for high-cost diagnostic radiopharmaceuticals in 2024. For more information, visit snmmi.org.

Nuclear Medicine 52

Nuclear Medicine Imaging Patient Care Disease 52

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Results demonstrated high detection rates (% positive PET scans) even at low PSA levels.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

OCTOBER 21, 2024

The first new feature,Centiloid scoring, standardizes the quantification of brain-amyloid plaque in PET scans across three commercially available beta-amyloid PET radiopharmaceuticals used to diagnose Alzheimer’s disease.

Disease 52

Disease Radiopharmaceuticals PET Scan Clinic 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 306

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 306

Open Medscience

MAY 14, 2024

Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically. The post Breakthroughs in Positron Emission Tomography Imaging appeared first on Open MedScience.

Imaging 40

Imaging Diagnostic Clinic Nuclear Medicine 40

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 130

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 130

AuntMinnie

NOVEMBER 21, 2024

Notably, the development of PET fibroblast activation protein inhibitor (FAPI) imaging agents – touted as having great potential in theranostics – appears to have reached a fever pitch. All studies in the sole slated session on novel radiopharmaceuticals this year are on FAPI-PET tracers. 8:40 a.m. | 2:30 p.m. |

Nuclear Medicine 264

Nuclear Medicine Imaging Radiopharmaceuticals Disease 264

Imaging Technology

JANUARY 14, 2025

Centers for Medicare and Medicaid Services (CMS) has announced key changes to reimbursement that make advanced imaging more accessible, lifting its one-scan-per-patient restriction in 2023 and unbundling payment for high-cost diagnostic radiopharmaceuticals in 2024.

Nuclear Medicine 52

Nuclear Medicine Imaging Patient Care PET Scan 52